Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 16, 2024
Data Byte
Trio of indications for Bimzelx among FDA’s September label expansions
Agency converts accelerated approvals of Filspari and Retevmo to full
BioCentury | Jul 23, 2024
Data Byte
Accelerated approvals of Epkinly, Augtyro, Krazati among FDA’s June label expansions
The month also brought conversions to full approval for Retevmo and Sirturo
BioCentury | Jun 18, 2024
Data Byte
FDA label expansions in May: Two new indications for BMS’s CAR T
Plus: Lilly’s RET inhibitor receives accelerated approval for younger patients
BioCentury | Jan 27, 2024
Data Byte
EMA’s CHMP confirms non-renewal of Translarna, denies new medicines Nezglyal and Syfovre
On the positive side of the ledger, BMS’s CAR T therapy Abecma headed for a line extension
BioCentury | Nov 3, 2023
Product Development
Innovating oncology evidence generation through new endpoints
Eli Lilly is among the companies pioneering alternative oncology endpoints to capture make-or-break nuances in data
BioCentury | Oct 24, 2023
Product Development
Lilly aims to change the conversation around precision oncology
With Phase III data at ESMO, Lilly hopes to make Retevmo a case study for success in precision oncology
BioCentury | Aug 25, 2023
Finance
Aug. 24 Quick Takes: Ferring banks $300M up front in Royalty Pharma deal
Plus: Aprinoia, SPAC terminate merger agreement and Exelixis’ cabozantinib shows PFS benefit in NETs and updates on the IRA, RSV and more
BioCentury | Aug 10, 2023
Finance
Aug. 9 Quick Takes: Alltrna raises $109M for unified approach to stop codon diseases
Plus: Venture cash for ADARx, Georgiamune, Neurophth and updates from Regeneron-Decibel, Novartis, Sunbird-Glympse, Denali-Takeda and more
BioCentury | Aug 9, 2023
Product Development
Amid leadership shift, Mirati plots label expansions
Mirati raises $300M follow-on following CEO change and signs of promising sales growth trajectory for KRAS inhibitor
BioCentury | Aug 5, 2023
Regulation
Aug. 4 Quick Takes: Sage-Biogen get FDA approval for one of two depression indications
Plus: Galapagos trims Jyseleca guidance, seeks options; and updates from Mesoblast, Lilly, Sino and more
Items per page:
1 - 10 of 206